- Home
- CPRX vs SUPN Comparison
CPRX vs SUPN Comparison
Compare CPRX & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPRX
- SUPN
- Stock Information
- Founded
- CPRX 2002
- SUPN 2005
- Country
- CPRX United States
- SUPN United States
- Employees
- CPRX N/A
- SUPN N/A
- Industry
- CPRX Biotechnology: Pharmaceutical Preparations
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- CPRX Health Care
- SUPN Health Care
- Exchange
- CPRX Nasdaq
- SUPN Nasdaq
- Market Cap
- CPRX 2.6B
- SUPN 2.6B
- IPO Year
- CPRX 2006
- SUPN 2012
- Fundamental
- Price
- CPRX $20.82
- SUPN $47.92
- Analyst Decision
- CPRX Strong Buy
- SUPN Buy
- Analyst Count
- CPRX 5
- SUPN 2
- Target Price
- CPRX $33.20
- SUPN $51.50
- AVG Volume (30 Days)
- CPRX 1.6M
- SUPN 682.2K
- Earning Date
- CPRX 11-05-2025
- SUPN 11-03-2025
- Dividend Yield
- CPRX N/A
- SUPN N/A
- EPS Growth
- CPRX 183.96
- SUPN 1411.53
- EPS
- CPRX 1.65
- SUPN 1.14
- Revenue
- CPRX $558,499,000.00
- SUPN $665,125,000.00
- Revenue This Year
- CPRX $16.51
- SUPN $6.71
- Revenue Next Year
- CPRX $9.58
- SUPN $19.74
- P/E Ratio
- CPRX $12.64
- SUPN $42.23
- Revenue Growth
- CPRX 28.55
- SUPN 5.55
- 52 Week Low
- CPRX $19.05
- SUPN $29.16
- 52 Week High
- CPRX $26.58
- SUPN $49.66
- Technical
- Relative Strength Index (RSI)
- CPRX 58.08
- SUPN 66.02
- Support Level
- CPRX $19.05
- SUPN $47.34
- Resistance Level
- CPRX $21.07
- SUPN $49.66
- Average True Range (ATR)
- CPRX 0.59
- SUPN 1.23
- MACD
- CPRX 0.16
- SUPN -0.08
- Stochastic Oscillator
- CPRX 60.27
- SUPN 66.70
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.